- Kitazume H, Iwama T, Kubo I, Ageishi Y, Suzuki A. Noreflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart) 1988; 116: 211-215.
- Piana RN, Paik GY, Moscucci M et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
- Abbo KM, Dooris M, Glazier S et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am ) Cardiol 1995; 75: 778-782.
- Kenner MD, Zajac EJ, Kondos GT et al. Ability of the noreflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one month followup. Am ) Cardiol 1995; 76: 861-867.
- lto H, Maruyama A, Iwakura K et al. Clinical implications of the 'no reflow' phenomenon. Circulation 1996; 93: 223-228.
- Baim DS, Carrozza JP. Understanding the 'no-reflow' problem. Cathet Cardiovasc Intervent 1996; 39: 7-8.
- Kaul U, Singh B, Sudan D et al. Primary stenting in acute myocardial infarction: a 30 days' follow up study. Cathet Cardiovasc Intervent 1999; 46: 4-10.
- Feld H, Lichstien E, Schachter J, Shani J. Early and late angiographie findings of the 'no-reflow' phenomenon following direct angioplasty as the primary treatment for acute myocardial infarction. Am Heart) 1992; 123: 782-784.
- Wilson RF, Laxson DD, Lesser )R, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; i (8642): 807-811.
- The EPIC investigators: use of a monoclonal antibody directed against the platelet glycoprotein lIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
- Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 45: 187-190.
Reversal of slow flow phenomenon during primary stenting by bail-out administration of abciximab
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.